Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections (ALRTIs) in children under five ...

A prominent paediatrician on Sunday urged people to take more precautions against a common virus known as RSV, saying cases ...

Estimates varied from 2008 through 2018, with RSV-associated antibiotic prescribing exceeding 10% in peak RSV years and ...

It starts with a sniffle. A mild cough. You tell yourself it’s just a cold—babies get those, right? But make no mistake. RSV ...

Each year, on November 12, we observe World Pneumonia Day to raise awareness about one of the most serious and often ...

A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections (The drug ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

The Food and Drug Administration (FDA) has approved Enflonsia ™ (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who ...

A major study presented today at ESCMID Global 2025 has revealed that adults with respiratory syncytial virus-associated ...

The panel, known as the Advisory Committee on Immunization Practice, is due to meet on June 25 and 26. It will vote on the ...

Respiratory syncytial virus (RSV) causes millions of childhood illnesses yearly, particularly in poorer countries. On 30 May 2025, the World Health Organisation issued its first global guidance ...